MolecuLight Corp. , the global leader in fluorescence imaging technology for the real-time detection of harmful bacteria in wound care, proudly reaffirms its commitment to equitable wound care with a recent publication by senior author Charles Andersen , MD , and colleagues, "Bacterial Fluorescence Imaging to Address Racial Inequities in Wound Infection Assessment," published in the journal Advances in Skin & Wound Care.

The article highlights systemic inequities in health care that fuel preventable suffering and premature death among racial and ethnic minority populations. One prominent example is the stark disparity in diabetes outcomes: National surveys led by the Centers for Disease Control and Prevention (CDC) found that in 2019, Black Americans were twice as likely to die from diabetes complications as white Americans . This alarming statistic is a grim reminder of the higher rates of diabetes, obesity, and other chronic health conditions affecting these communities, driven by a complex web of factors including limited access to and suboptimal quality of health care.

Disproportionately poor health outcomes are nearly universal for Black Americans, including wounds. Between 2013 and 2014, Black Americans with diabetic ulcers in rural areas faced twice the risk of leg amputation or death after hospitalization compared with their white counterparts living in similar regions ii : “There are now technologies that can identify more Black patients with wound infections who can be treated more effectively to prevent complications of infection, including gangrene, sepsis, and amputations,” explained Dr. Jonathan Johnson , a co-author of the study and a health equity advocate.

As Dr. Johnson explained, “Delayed diagnosis of wound infection is a major driver of poor outcomes as it delays intervention. This allows infections to fester and become more severe, as highlighted in our article on MolecuLight and healthcare equity. Wound assessment tools that promote timely and equitable detection of infections should be a focus for all stakeholders, including providers, payers, and policymakers.”

“Historically, medical curricula have not equipped wound care physicians with the knowledge and skills necessary to accurately identify signs of infection in dark skin. Textbooks are dominated by Caucasian skin examples, leaving physicians unaware that classic signs such as erythema can manifest as burgundy or deep purple on darker skin,” said Charles Andersen , MD , a renowned vascular surgeon and senior author on the paper. He added, “This critical gap in training has devastating consequences, especially for Black diabetic patients, who often present with the most subtle signs of wound infection. MolecuLight fluorescence imaging offers a solution to this critical problem, equipping physicians with a unique, objective tool that detects bacteria regardless of skin tone, enabling faster intervention, more precise treatment, and reduced complications.”

MolecuLight’s unique ability to instantly detect bacteria in wounds, regardless of skin tone, enables clinicians to make timely and informed treatment decisions, improving patient outcomes and promoting equitable care. FDA-cleared Class II MolecuLight devices are sold and distributed worldwide for bacteria detection and wound treatment. The MolecuLight procedure is reimbursable in all states in the United States. According to Anil Amlani, CEO of MolecuLight. “Our goal is to make MolecuLight technology as accessible as possible and bridge the health equity gap. We believe this is critical to supporting equitable wound care in underserved populations, who often face reduced access to quality healthcare and emerging diagnostics.”

About MolecuLight Corp.

MolecuLight Corp.  is a privately held, global imaging company that manufactures and markets the MolecuLight  i:X ® and DX™ wound imaging devices . These are the only FDA-cleared Class II medical imaging devices for real-time detection of elevated bacterial loads in wounds . They also provide accurate digital measurement of wounds for comprehensive wound care, backed by robust clinical evidence including over 100 peer-reviewed publications.



Source: prnewswire.com

Report Abuse